Clinical commissioning policy: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Document first published:
Page updated:
Topic:
Publication type:

Canakinumab is not recommended to be available as a routine commissioning treatment option for adults and children 2 years and over with Still’s disease refractory to treatment with (or do not tolerate) anakinra and tocilizumab within the criteria set out in this document.